Click on your country to go to the Order and check out page where you are.USA - Australia - Canada - S.Africa - New Zealand - U.K.
...with Glucosamine, a leading supplement for cartilage formation and repair.
November 30, 2005 08:30 AM US Eastern Timezone
SAN DIEGO--(BUSINESS WIRE)--Nov. 30, 2005--Imagenetix, Inc. (OTCBB:IAGX), a company focused
on inflammation and inflammation-related markets, today said its Celadrin(R) supplement for joint
health and mobility is now available combined with Glucosamine, a leading supplement
for cartilage formation and repair.
The new Glucosamine/Celadrin(R) combination is expected to produce enhanced action of its two components, resulting in improved joint mobility and comfort.
The new product is now being marketed by several nutritional brands and is currently available at some 30,000 drug chain and mass market retail outlets across the U.S. and Canada, including Wal-Mart, GNC, Vitamin Shoppe, Longs Drugs, Fred Meyer, Grant, Walgreens, Tops, Shaws, OscoDrug/Sav-on Drugs, Happy Harry's, Sun Harvest and Whole Foods.
Celadrin(R) is a natural-based product proven in clinical trials to enhance joint flexibility and mobility with no side effects. The product works by supporting the lubrication of joints and enhancing fluids that cushion bones and joints.
Glucosamine is a natural amino-monosaccharide which stimulates production of chondrocytes, the cells which comprise cartilage. With 2004 worldwide sales in excess of $2 billion, Glucosamine is among the world's leading supplements for cartilage repair.
Imagenetix CEO William P. Spencer said, "We are excited to have launched this groundbreaking product. We believe the Glucosamine/Celadrin(R) combination, with its synergy of lubrication and cartilage-building compounds, will establish a significant niche in the nutritional supplement market and contribute materially to Imagenetix top- and bottom-line performance in the years to come."
Imagenetix, Inc. (IAGX), develops, formulates, private-labels, and produces nutritional supplements, over-the-counter topical creams, skin care products and pharmaceuticals for inflammatory-related markets.
Safe Harbor Statement
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.